New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 7, 2013
10:38 EDTGWPHGW Pharmaceuticals soars after analyst nearly triples price target
Shares of Britain's GW Pharmaceuticals (GWPH) are jumping after a Lazard Capital analyst wrote that the company has one of the most compelling opportunities he's ever seen, and nearly tripled his price target on the stock. WHAT'S NEW: GW's CBD, a drug derived from the cannabis plant, has significantly helped some epilepsy patients to whom it has been administered, Lazard Capital analyst Joshua Schimmer wrote in a note to investors earlier today. Although not all the refractory childhood seizure patients who have taken the drug have improved, evidence suggests that the treatment does have "an antiseizure effect," the analyst believes after speaking with multiple experts. Moreover, "there is an enormous unmet need" for such an antiseizure treatment, and specialists appear to be extremely interested in CBD, Schimmer contended. He hiked his price target on GW to $65 from $22, and kept a Buy rating on the shares. TODAY'S PRICE ACTION: In mid-morning trading, GW rallied $5.95, or 24%, to $30.65.
News For GWPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2015
06:01 EDTGWPHGW Pharmaceuticals selloff yesterday an overreaction, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says shares of GW Pharmaceuticals sold off yesterday in response to an abstract posted for the American Epilepsy Society conference in December describing a single center's experience with Epidiolex for seizures. The results support the drug's potent activity in Dravet syndrome, but some investors have concern with the drop-out rate due to inactivity and the lower response rate compared to what has otherwise been described for Epidiolex, Schimmer told investors last night in a research note titled "Over-Reacting To A Tree When The Forest Remains In Good Shape." The dropout rate is likely a result of the center's "highly questionable" practice of stopping drug if seizure reduction doesn't reach 50%, while the lower response rate at one site shouldn't detract from a "much bigger, robust clinical experience spanning multiple centers," Schimmer argues. He reiterates an Overweight rating on GW with a $147 price target. The stock closed yesterday down $5.42 to $82.30.
November 19, 2015
15:33 EDTGWPHGW Pharmaceuticals drops 10% after epilepsy study abstract posted
The conclusion of the abstract, posted to the the site of the American Epilepsy Society, stated: "Add-on pure CBD was associated with more than 50% seizure reduction in one-third of patients at 3 months...Best results were obtained in patients with Dravet syndrome, although one experienced a severe increase in seizure frequency."
15:31 EDTGWPHAbstract for GW Pharmaceuticals epilepsys study posted to AES site
Subscribe for More Information
November 16, 2015
07:16 EDTGWPHHayman Capital gives quarterly update on stakes
NEW STAKES: Impax (IPXL), CF Industries (CF), GW Pharmaceuticals (GWPH), ProNAi Therapeutics (DNAI). INCREASED STAKES: BioMarin (BMRN), NMI Holdings (NMIH), Vertex (VRTX), Endo (ENDP). DECREASED STAKES: Mylan (MYL). LIQUIDATED STAKES: Perrigo (PRGO), Oasis Petroleum (OAS), Whiting Petroleum (WLL), Newfield Exploration (NFX), SM Energy (SM).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use